{"id":"ciprofloxacin-bayo9867","safety":{"commonSideEffects":[{"rate":"3-17%","effect":"Nausea"},{"rate":"2-16%","effect":"Diarrhea"},{"rate":"1-2%","effect":"Vomiting"},{"rate":"1-7%","effect":"Abdominal pain"},{"rate":"1-3%","effect":"Headache"},{"rate":"1-3%","effect":"Dizziness"},{"rate":"<1%","effect":"Tendinopathy/tendon rupture"},{"rate":"<1%","effect":"QT prolongation"},{"rate":"<1%","effect":"Photosensitivity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a fluoroquinolone antibiotic, ciprofloxacin binds to and inhibits DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for bacterial DNA supercoiling and separation. This dual inhibition disrupts DNA replication and transcription, leading to rapid bactericidal activity against a broad spectrum of gram-negative and gram-positive organisms.","oneSentence":"Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:58.100Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections (respiratory tract, urinary tract, gastrointestinal, skin and soft tissue)"},{"name":"Anthrax (inhalational exposure prophylaxis and treatment)"}]},"trialDetails":[{"nctId":"NCT06798402","phase":"PHASE2","title":"Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate","status":"RECRUITING","sponsor":"Al-Mustafa University College","startDate":"2025-02-07","conditions":"Cutaneous Leishmaniasis","enrollment":80},{"nctId":"NCT00668044","phase":"PHASE3","title":"Ciprofloxacin on Burned Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-11","conditions":"Burns, Bacterial Infections","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ciprofloxacin (BAYO9867)","genericName":"Ciprofloxacin (BAYO9867)","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria. Used for Bacterial infections (respiratory tract, urinary tract, gastrointestinal, skin and soft tissue), Anthrax (inhalational exposure prophylaxis and treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}